Michael H. Davidson

October 14, 2026

NewAmsterdam Pharma's SPINOZA Trial May Shift Alzheimer Strategy. NewAmsterdam Pharma is conducting a genotype‑targeted SPINOZA trial that could alter its long‑term Alzheimer approach. The study focuses on personalized treatment based on genetic markers. Results may influence the company's future research priorities.

October 11, 2026

RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.

October 9, 2026

Tenax Pauses TNX-103 Trial Enrollment, Seeks FDA Meeting. Tenax Therapeutics has temporarily paused enrollment in its LEVEL-2 trial for TNX-103 to amend study criteria. The company has also requested a meeting with the FDA to discuss these changes. This development is significant as it involves a key clinical trial, and the stock is currently trading near its 52-week low.

October 5, 2026

Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.